Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
The advent of immunotherapy, especially checkpoint inhibitor-based immunotherapy, has
provided novel and powerful weapons against cancer. Because only a subset of cancer …
provided novel and powerful weapons against cancer. Because only a subset of cancer …
Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes
SI Kim, CR Cassella, KT Byrne - Frontiers in immunology, 2021 - frontiersin.org
Cancer immunotherapy has revolutionized the treatment landscape in medical oncology, but
its efficacy has been variable across patients. Biomarkers to predict such differential …
its efficacy has been variable across patients. Biomarkers to predict such differential …
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Immune checkpoint inhibitors have been successful across several tumor types; however,
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10 …
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10 …
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Oncogene-targeted therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated
protein kinase kinase (MEK) inhibitors induces a high initial response rate in patients with …
protein kinase kinase (MEK) inhibitors induces a high initial response rate in patients with …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - Nature medicine, 2019 - nature.com
Abstract Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor
responses that are induced by the combined inhibition of BRAF and MEK. Here we …
responses that are induced by the combined inhibition of BRAF and MEK. Here we …
[HTML][HTML] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
[HTML][HTML] Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: current status in clinical trials
Y Song, Z Bi, Y Liu, F Qin, Y Wei, X Wei - Genes & diseases, 2023 - Elsevier
Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
[HTML][HTML] ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Z Wang, X Wu - Cancer medicine, 2020 - Wiley Online Library
Immunocheckpoint proteins of tumor infiltrating lymphocytes play an important role in tumor
prognosis in the course of tumor clinicopathology. PD‐1 (Programmed cell death protein 1) …
prognosis in the course of tumor clinicopathology. PD‐1 (Programmed cell death protein 1) …
Combining immune checkpoint inhibitors with conventional cancer therapy
Y Yan, AB Kumar, H Finnes, SN Markovic… - Frontiers in …, 2018 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing
unprecedented clinical benefits. However, primary or acquired therapy resistance can affect …
unprecedented clinical benefits. However, primary or acquired therapy resistance can affect …